Neoantigens for all

Nouscom AG has a simplified neoantigen platform that cuts production time, designed to deliver vaccines to cancer patients more quickly than the standard methods. With a two-pronged approach, the company is developing both personalized vaccines and off-the-shelf ones that could become first in class.

Nouscom’s platform is unique in using replication-deficient Great Apes Adenovirus vectors as a prime and Modified Vaccinia Virus Ankara vectors as a boost, each of which encodes up to 100 neoantigens. ...